What's New

FDA Approves Use of Truvada as PrEP

The U.S. Food and Drug Administration decided on 16 July 2012 to approve the use of an HIV treatment drug for reducing the risk of acquiring HIV.

Read the press release

(July 16, 2012)

Partners PrEP Study results published

Findings showed that using hormonal contraceptives doubled an HIV uninfected woman's chances of becoming infected with HIV.

Read the article
Read the press release

(July 11, 2012)

Hormonal Contraception Increases HIV Risk

Findings showed that using hormonal contraceptives doubled an HIV uninfected woman's chances of becoming infected with HIV.

Read the article
Read the WHO Technical Statement (PDF)

(October 04, 2011)

Partners PrEP Study: Effectiveness Confirmed!

Pivotal study finds that HIV medications are highly effective as prophyalxis against HIV infection in men and women in Africa.

Read the press release

(July 13, 2011)

iPrEx: Pill Reduces HIV

iPrEx, a major study published in the New England Journal of Medicine demonstrates the effectiveness of a new HIV prevention tool, Pre-Exposure Prophylaxis (PrEP).

Read the press release
Read the Partners PrEP Statement

(November 23, 2010)

Vaginal Microbicide Gel Shows Potential

The state of microbicide development, safety and efficacy data from CAPRISA 004 and implications of the CAPRISA 004 trial results for the microbicide and PrEP field were recently discussed in Vienna, Austria.

Read the press release
Watch the webcast

(July 20, 2010)

Partners HSV/HIV ART Results Published

"Provision of ART to HIV-1 infected patients could be an effective strategy to achieve population-level reductions in HIV-1 transmission." -- Deborah Donnell, corresponding author

Read the article

(May 27, 2010)

Pregnancy Doubles HIV Risk in Men

"While a number of studies have shown that during pregnancy women are at increased risk of acquiring HIV from an infected partner, a new study has found pregnancy is a time when men also are at greater risk– double the risk, in fact." -- CROI

Read the press release

(May 23, 2010)

ART Couples Strategy Cuts HIV Transmission

"Antiretroviral treatment is highly effective at reducing risk of HIV transmission to uninfected partners, prospective data has affirmed. The 92% reduction in risk of transmission dropped the incidence of in-couple transmission from 2.23% to 0.39%, found Deborah Donnell, PhD, of the Fred Hutchinson Cancer Research Center in Seattle." -- Medpage Today

Read the article

(February 18, 2010)

Partners HSV/HIV Disease Progression Results Published

"A common treatment for herpes can delay the need for HIV drugs in people with both infections, say US researchers." -- BBC

Read the article
BBC coverage

(February 15, 2010)

Partners HSV/HIV Transmission Results Published

"Herpes medication does not reduce risk of HIV transmission from individuals with HIV and genital herpes but leads to new important insights about HIV transmission, UW-led international study finds." -- UW Medicine

Read the article

(February 4, 2010)

Bill Gates visits Partners PrEP in Eldoret, Kenya

Bill Gates, co-chair of the Bill & Melinda Gates Foundation, visited the Eldoret Partners PrEP study site on December 3, 2009.

Read about it

(December 3, 2009)

Can a pill a day stop new HIV infections?

"A powerful new HIV prevention tool may be on the horizon. Scientists are saying they could be on the verge of ascertaining whether taking anti-retroviral drugs before exposure to HIV could be an effective prevention tool. The Pre-exposure prophalyxis (PrEP) trial is going on in Botswana, Kenya, Uganda, South Africa, Thailand and USA. African researchers involved in the study say they are “very hopeful”" -- The Independent

Read the article

(April 1, 2009)

PrEP Cost Effectiveness

"The combination of tenofovir and emtricitabine shows promise as HIV preexposure prophylaxis (PrEP). We sought to forecast clinical, epidemiologic, and economic outcomes of PrEP, taking into account uncertainties regarding efficacy, the risks of developing drug resistance and toxicity, behavioral disinhibition, and drug costs" -- Clinical Infectious Diseases

Read the article

(March 15, 2009)

Scientists Debate HIV Prevention Products

"For years now, scientists have tried to find a product that would give women in developing countries more control in protecting themselves against sexually transmitted HIV. They have yet to find a universally effective and safe method. A recent study presented at the Conference on Retroviruses and Opportunistic Infections in Montreal highlighted the dilemmas in this field. . . ." -- npr

Read the article

(March 10, 2009)

A preemptive strike against HIV

"Researchers are enrolling thousands of participants around the world in clinical trials in a massive effort to test whether a once-daily pill can prevent HIV. Cassandra Willyard explores why they are optimistic the strategy will work and why it might be difficult to implement." -- Nature Medicine

Read the article

(February 1, 2009)

PrEP: future implementation challenges

"Researchers are enrolling thousands of participants around the world in clinical trials in a massive effort to test whether a once-daily pill can prevent HIV. Cassandra Willyard explores why they are optimistic the strategy will work and why it might be difficult to implement." -- Future Medicine

Read the article

(January 9 2009)

New hope for HIV-discordant couples

"A new clinical trial to test the effectiveness of pre-exposure prophylaxis in stable sexual relationships has started in Uganda, with 3,900 discordant couples enrolled in a five-year study." -- PlusNews

Read the article

(November 14, 2008)

Kampala team enrolls first couple in the Partners PrEP Study

The Partners PrEP Study has officially started. The first discordant couple was enrolled at the Kampala, Uganda site on July 3, 2008.

(July 3, 2008)

HPTN 039 results in The Lancet

Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial.

Read the summary

(June 21, 2008)

2008 National STD Prevention Conference presentation

On March 12, 2008 Connie Celum presented "HSV-HIV Interactions: Results of the HPTN 039 Study and Beyond" at the 2008 National STD Prevention Conference in Chicago, IL.

See the presentation

(March 12, 2008)

(Back to top)

Member login

Search this Site | Contact Us